H.C. Wainwright analyst Arthur He initiated coverage of Adaptimmune Therapeutics with a Buy rating and $4 price target. Adaptimmune is a clinical-stage biopharmaceutical company focused on developing novel T cell therapies in oncology based on its proprietary T-cell receptor platform, the analyst tells investors in a research note. The firm believes the company has the potential to reshape the treatment landscape for solid tumors by leveraging its integrated TCR-T platform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAP:
- Adaptimmune Enhances Severance Benefits for Executives
- Adaptimmune Enhances Executive Severance and Benefit Terms
- Biotech Alert: Searches spiking for these stocks today
- Adaptimmune collaboration with Galapagos a ‘rational move,’ says Wells Fargo
- Adaptimmune Inks Lucrative Deal for Cancer Therapy Trial
Questions or Comments about the article? Write to editor@tipranks.com